Re: Separation and Consulting Agreement Dear Bill:Adamas Pharmaceuticals Inc • August 8th, 2017 • Pharmaceutical preparations • California
This letter sets forth the substance of the separation agreement (the “Agreement”) that Adamas Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition.
SECURED PROMISSORY NOTE (Initial Tranche Loan)Adamas Pharmaceuticals Inc • August 8th, 2017 • Pharmaceutical preparations • New York
THIS NOTE AND THE OBLIGATIONS REPRESENTED HEREBY MAY NOT BE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE TERMS AND PROVISIONS OF THE LOAN AGREEMENT REFERRED TO BELOW. TRANSFERS OF THIS NOTE AND THE OBLIGATIONS REPRESENTED HEREBY MUST BE RECORDED IN THE REGISTER MAINTAINED BY THE BORROWER PURSUANT TO THE TERMS OF THE LOAN AGREEMENT. IN ADDITION, THIS NOTE MAY NOT BE OFFERED, SOLD, PLEDGED, HEDGED OR OTHERWISE TRANSFERRED WITHOUT THE PRIOR WRITTEN CONSENT OF THE BORROWER, WHICH CONSENT SHALL, FOR PURPOSES OF THIS SENTENCE, BE DEEMED TO HAVE BEEN GIVEN UPON THE REQUEST OF THE HOLDER HEREOF.
LOAN AGREEMENT Dated as of May 11, 2017 Between HEALTHCARE ROYALTY PARTNERS III, L.P., as Lender, and ADAMAS PHARMA, LLC, as BorrowerLoan Agreement • August 8th, 2017 • Adamas Pharmaceuticals Inc • Pharmaceutical preparations • New York
This LOAN AGREEMENT (this “Agreement”) dated as of May 11, 2017, is entered into by and between the entities managed by HealthCare Royalty Partners III, L.P., as lender (“Lender”), and ADAMAS PHARMA, LLC, a Delaware limited liability company, as borrower (“Borrower”).
